Abstracts tagged "monoclonal antibodies"

Abstract Number: L1 • 2014 ACR/ARHP Annual Meeting
Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis: 24-Week Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using Subcutaneous Dosing
Iain B. McInnes^1,2, Philip J. Mease³, Bruce Kirkham⁴, Arthur Kavanaugh⁵, Christopher T. Ritchlin⁶, Proton Rahman⁷, Désirée van der Heijde⁸, Robert B. M. Landewé⁹, Philip G. Conaghan¹⁰, Hanno Richards¹¹, Gregory Ligozio¹², Luminita Pricop¹³ and Shephard Mpofu¹⁴, ¹University of Glasgow, Glasgow, Scotland, ²University of Glasgow, Glasgow, United Kingdom, ³Swedish Medical Center and University of Washington, Seattle, WA, ⁴Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, ⁵UC San Diego School of Medicine, La Jolla, CA, ⁶Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁷Memorial University, St John's, NF, Canada, ⁸Leiden University Medical Center, Leiden, Netherlands, ⁹University of Amsterdam and Atrium Medical Center, Amsterdam, Netherlands, ¹⁰University of Leeds, Leeds, United Kingdom, ¹¹Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland, ¹²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹³Integrated Hospital Care (IHC) Franchise, Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁴Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab, a human anti–IL-17A monoclonal antibody, has shown efficacy in the treatment of psoriasis in phase 3 studies with subcutaneous (s.c.) dosing as well…
Abstract Number: 1492 • 2014 ACR/ARHP Annual Meeting
Safety and Tolerability of NNC01140006, an Anti-IL-21 Monoclonal Antibody, at Multiple s.c. Dose Levels in Patients with Rheumatoid Arthritis
Frank Wagner¹, Birte Skrumsager² and Sergey Fitilev³, ¹Charité Research Org GmbH, Berlin, Germany, ²Novo Nordisk A/S, Søborg, Denmark, ³Department of Clinical Pharmacology, Municipal Clinic #2, Moscow, Russia
Background/Purpose A phase 1, randomised, double-blind, placebo-controlled, dose-escalation trial was conducted to assess the safety and tolerability of the anti-IL-21-antibody NNC0114-0006, in patients with active…
Abstract Number: 989 • 2014 ACR/ARHP Annual Meeting
Fcgamma Receptor IIb Facilitates Rapid Internalisation of Rituximab (type 1 anti-CD20 antibody) in B Cells from Patients with RA and SLE and Contributes to Less Efficient B Cell Lysis Than Type 2 Anti-CD20 Antibodies, in Vitro
Venkat Reddy¹, Geraldine Cambridge², David A. Isenberg³, Mark Cragg⁴ and Maria J. Leandro², ¹Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ²Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ³Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁴Antibody and Vaccine group, Cancer Sciences Unit, Faculty of Medicine, Southampton University, Southampton, United Kingdom
Background/Purpose Incomplete B-cell depletion using rituximab (RTX) is associated with poor clinical response in some individuals with RA and SLE, in particular. However, the precise…
Abstract Number: 2358 • 2013 ACR/ARHP Annual Meeting
Sarilumab, a Subcutaneously Administered, Fully Human Monoclonal Antibody Inhibitor Of The IL-6 Receptor Alpha: 12 Week Infection Rates By Level Of Circulating Neutrophils In Rheumatoid Arthritis and Ankylosing Spondylitis
Kevin L. Winthrop¹, Tanya Momtahen², Stefano Fiore³, Steven P. Weinstein⁴, Janet van Adelsberg⁵, Richard Wu⁶ and Neil Graham⁷, ¹Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ²Program Direction, Sanofi, Bridgewater, NJ, ³Clinical Science, Sanofi, Bridgewater, NJ, ⁴Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ⁵Clinical Science, Regeneron Pharmaceutials, Inc., Tarrytown, NY, ⁶BioStatistics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁷Program Direction, Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Sarilumab is a human monoclonal antibody directed against the alpha subunit of the IL-6 receptor (IL-6Rα). IL-6 blockade is associated with a reduction in…
Abstract Number: 2142 • 2013 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy Of Subcutaneous Tanezumab In Patients With Knee Or Hip Osteoarthritis (NCT00994890)
Leslie Tive¹, Eugene J. Dabezies², Robert J. Fountaine³, Mark T. Brown³, Michael D. Smith³, Kenneth M. Verburg³ and Christine R. West⁴, ¹Arthritis, Pfizer Inc, New York, NY, ²Pensacola Research Consultants, Pensacola, FL, ³Pfizer, Inc., Groton, CT, ⁴Clinical Sciences, Pfizer, Williamston, MI
Background/Purpose : Tanezumab (TNZ), a monoclonal antibody that inhibits nerve growth factor, reduces hip or knee osteoarthritis (OA) pain. A non-controlled, randomized, double-blind study of…
Abstract Number: 2343 • 2012 ACR/ARHP Annual Meeting
The Therapeutic Antibody Tregalizumab (BT-061) Induces Activation of Regulatory T Cells by Engaging a Unique CD4 Mediated Signaling That Strongly Differs From Signaling Events Induced by Standard Anti-CD4 Antibodies
Bianca Helling¹, Benjamin Daelken¹, Holger Wallmeier², Silke Aigner¹, Chantal Zuber¹, Martin Koenig¹, Andre Engling¹, Frank Osterroth¹, Niklas Czeloth³ and Christoph Uherek¹, ¹Biotest AG, Dreieich, Germany, ²Condor Scientific Computing & Consulting, Sulzbach, Germany, ³Global Research Immunology, Biotest AG, Dreieich, Germany
Background/Purpose: The humanized CD4 specific monoclonal antibody (mAb) tregalizumab is currently being tested in phase II clinical trials in Rheumatoid Arthritis. In contrast to other…
Abstract Number: 1337 • 2012 ACR/ARHP Annual Meeting
Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of the IL-6 Receptor: Pharmacokinetic Profile and Its Relationship to Changes in Pharmacodynamic Markers in Patients with Rheumatoid Arthritis
Pavel Belomestnov¹, Jennifer Hamilton², A. Thomas DiCioccio¹, Martine Jasson³ and Allen R. Radin⁴, ¹Pharmacometrics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ²Predictive Medicine, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Clinical Development, Sanofi-Aventis, Paris, France, ⁴Translational Medicine, Regeneron Pharmaceuticals Inc, Tarrytown, NY
Background/Purpose: Sarilumab, a fully human monoclonal antibody targeting interleukin-6 receptor alpha (IL-6Rα), is being evaluated for the treatment of rheumatoid arthritis (RA) based on the…
Abstract Number: 331 • 2012 ACR/ARHP Annual Meeting
PDL241, a Novel Humanized Monoclonal Antibody, Reveals CD319 As a Therapeutic Target for Rheumatoid Arthritis
Michel P.M. Vierboom¹, Jacky Woo², Hakju Kwon², Debra Chao², Shiming Ye², Jianmin Li², Karen Lin², Irene Tang², Nicole Belmar², Taymar Hartman², Elia Breedveld¹, Bert A. ‘t Hart¹ and Gary C. Starling², ¹Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, Netherlands, ²Abbott Biotherapeutics, Redwood City, CA
Background/Purpose: Current therapies have shown tremendous progress in the treatment of rheumatoïd arthritis (RA). However, a substantial group of RA patients are still refractory to…
Abstract Number: 259 • 2012 ACR/ARHP Annual Meeting
Long-Term Tanezumab Treatment for Osteoarthritis: Efficacy and Safety Results
Alfonso E. Bello¹, Evan F. Ekman², David Radin³, Isabelle Davignon⁴, Michael D. Smith⁵, Mark T. Brown⁵, Christine R. West⁶ and Kenneth M. Verburg⁵, ¹Illinois Bone & Joint Institute, Glenview, IL, ²Southern Orthopaedic Sports Medicine, Columbia, SC, ³Stamford Therapeutics Consortium, Stamford, CT, ⁴Pfizer, Groton, CT, ⁵Pfizer, Inc., Groton, CT, ⁶Clinical Sciences, Pfizer, Williamston, MI
Background/Purpose: Nerve growth factor (NGF) levels are associated with increased pain perception and are elevated in joints of arthritis patients. Tanezumab, a humanized monoclonal antibody,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.